Jörn Aldag
Chief Executive Officer bij HOOKIPA PHARMA INC.
Vermogen: 97 049 $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Sander J. van Deventer | M | 69 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands.
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 23 jaar |
Jean-Paul Clozel | M | 69 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 7 jaar |
Mathieu Simon | M | 68 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 5 jaar |
Graziano Seghezzi | M | 55 |
GeneSpire Srl
GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy.
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 13 jaar |
Peter Harwin | M | 38 | 4 jaar | |
André Muller | M | 60 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 7 jaar |
Daniel D. Pinschewer | M | 49 |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 13 jaar |
William Burns | M | 76 | 7 jaar | |
Matt Kapusta | M | 51 | 9 jaar | |
Julien Gander | M | 45 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 7 jaar |
Jan van de Winkel | M | 63 |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 7 jaar |
Steven Holtzman | M | 70 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 11 jaar |
Michael Kelly | M | 67 |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 5 jaar |
Julie O'Neill | F | 58 | 6 jaar | |
Karen Ferrante | M | 66 | 6 jaar | |
Paula Soteropoulos | F | 56 | 11 jaar | |
Paul-Henri Lambert | M | 85 |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 9 jaar |
David Kaufman | M | 51 | 5 jaar | |
Srishti Gupta | M | 48 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 3 jaar |
Klaus Orlinger | M | 46 | 12 jaar | |
Christian Klemt | M | 51 | 9 jaar | |
Jessica Sachs | M | 49 | 7 jaar | |
Mary Coelho | F | 62 | 1 jaar | |
Chris Cain | M | 40 | 4 jaar | |
Daniel Steiner | M | - | 13 jaar | |
Tony Melckenbeek | M | - | - | |
Julia Berretta | M | 43 |
GeneSpire Srl
GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy. | 4 jaar |
Daniel Courtney | M | - | 6 jaar | |
Timothy Reilly | M | 50 | 2 jaar | |
Matthew Ros | M | 57 | 5 jaar | |
Andrew C. Weiss | M | 55 | 7 jaar | |
Sandy Mahatme | M | 59 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 4 jaar |
John Green | M | 43 | 6 jaar | |
Peter Kellogg | M | 67 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 3 jaar |
Felix R. Ehrat | M | 67 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 4 jaar |
Roman Necina | M | 56 | 5 jaar | |
Reinhard Kandera | M | 54 | 7 jaar | |
Arlene Morris | F | 72 | 5 jaar | |
Rolf M. Zinkernagel | M | 80 |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 13 jaar |
Sara Saltzman | F | - | 5 jaar | |
Debora Spar | M | 60 |
Harvard Business School
| 33 jaar |
Lucia Faccio | M | - |
GeneSpire Srl
GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy. | 4 jaar |
Alberto Gimona | M | 64 | 5 jaar | |
Arnaud Marchant | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
Franz Heinz | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
Vera Strasser | F | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
Heidi Feik | F | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
Markus Hosang | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
Simon Jose | M | 58 | 6 jaar | |
Graeme Martin | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | - |
Sophie Kornowski-Bonnet | M | 61 | 1 jaar | |
Alexander Khatuntsev | M | 45 | 7 jaar | |
Lukas Flatz | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 13 jaar |
Andreas Bergthaler | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 13 jaar |
Malte Peters | M | 61 | 1 jaar | |
Das Narayandas | M | 63 |
Harvard Business School
| 30 jaar |
Tarun Khanna | M | 57 |
Harvard Business School
| 31 jaar |
Daniela Bellomo | M | 56 |
GeneSpire Srl
GeneSpire Srl BiotechnologyHealth Technology GeneSpire Srl is a holding company, which engages in the development of transformative gene therapies for patients with genetic diseases. The company was founded by Luigi Naldini and Alessio Cantone in March 2020 and is headquartered in Milan, Italy. | - |
Nils Aldag | M | - |
DESERTEC Foundation
| - |
Martine Clozel | M | 68 | 7 jaar | |
Benjamin Esty | M | 61 |
Harvard Business School
| 31 jaar |
Frank Kalkbrenner | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 11 jaar |
Victor Paulus | M | - | 6 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Philip Astley-Sparke | M | 52 | 8 jaar | |
Hugo Slootweg | M | 53 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 8 jaar |
François Meyer | M | 76 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 4 jaar |
Joseph Feczko | M | 75 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 6 jaar |
Christiana Stamoulis | F | 53 | 4 jaar | |
Ferdinand Verdonck | M | 81 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 4 jaar |
Bruce Booth | M | 49 | 6 jaar | |
David Schaffer | M | 53 | 6 jaar | |
Christian Zahnd | M | 49 | 12 jaar | |
Piers John Morgan | M | 57 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 5 jaar |
Liam Ratcliffe | M | 60 | 4 jaar | |
Philippe van Holle | M | 69 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 15 jaar |
Harald Petry | M | 65 |
Amsterdam Molecular Therapeutics (AMT) Holding NV
Amsterdam Molecular Therapeutics (AMT) Holding NV Miscellaneous Commercial ServicesCommercial Services Amsterdam Molecular Therapeutics (AMT) Holding NV engages in the development of human gene based therapies. The company has a product pipeline of several gene therapy products in development for hemophilia B, acute intermittent porphyria, Parkinson's disease and SanfilippoB. It is expected to be finally dissolved in September 2012. Amsterdam Molecular Therapeutics (AMT) Holding was founded by Sander J. H. van Deventer and John J. P. Kastelein on March 20, 1998 and is headquartered in Amsterdam, Netherlands. | 10 jaar |
Ulrich Aldag | M | - | 5 jaar | |
Katherine Cohen | M | - |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Hookipa Biotech AG develops new generation prophylactic and therapeutic vaccines. The firm’s Vaxwave technology is a novel immunotherapy platform using a replication-defective viral vector for the prevention and treatment of cancer and infectious diseases. The company was founded by Lukas Flatz, Andreas Bergthaler, Rolf M. Zinkernagel and Daniel Pinschewer in July 2011 and is headquartered in Vienna, Austria. | 5 jaar |
Christoph S. Lengauer | M | 59 | 4 jaar | |
Jean-Charles Soria | M | 53 | - | |
Eva M. Mulder | F | - | 5 jaar | |
Christine D. Baker | F | 58 | 5 jaar | |
Debi Kleiman | M | - |
Harvard Business School
| 2 jaar |
Klaus Maleck | M | 51 | - | |
Katia Schlienger | M | 62 | 2 jaar | |
Will Lewis | M | 55 | - | |
Flemming Ørnskov | M | 66 | - | |
Robert Perez | M | 59 | 1 jaar | |
Manfred Eigen | M | - | 5 jaar | |
Göran Albert Ando | M | 75 | 10 jaar | |
Scott Friend | M | 59 |
Harvard Business School
| 2 jaar |
Don Soland | M | 65 | 1 jaar | |
Matthew Osborne | M | - | 1 jaar | |
Anders Lilja | M | - | 7 jaar | |
Dirk H. Ehlers | M | 63 | 6 jaar | |
Timm H. Jessen | M | 62 | 7 jaar | |
Jean-Pierre Garnier | M | 75 |
Idorsia Pharmaceuticals Ltd.
Idorsia Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Part of Idorsia Ltd., Idorsia Pharmaceuticals Ltd. is a Swiss company that aims to discover, develop, and provide innovative medicines to patients. The private company is based in Allschwil, Switzerland. The company has created an eBook that provides useful information about Fabry disease, a rare inherited disorder caused by the build-up of a fat-like substance in the cells of the body organs. Jean-Paul Clozel has been the CEO of the company since 2017. | 3 jaar |
Randall Mays | M | 58 |
Harvard Business School
| 2 jaar |
James Schenck | M | 57 |
Harvard Business School
| 2 jaar |
Ralph Z. Sorenson | M | 90 |
Harvard Business School
| 3 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 44 | 44.00% |
Zwitserland | 20 | 20.00% |
Nederland | 17 | 17.00% |
Oostenrijk | 17 | 17.00% |
Duitsland | 7 | 7.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Jörn Aldag
- Persoonlijk netwerk